Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Supplementary Table S3: Targeted Sequencing Panel. List of regions included in the CHARM+EVOLVE panel used for targeted sequencing; coordinates are for human reference hg38.

补充表 S3：靶向测序阵列。列出用于靶向测序的 CHARM+EVOLVE 阵列所包含的区域；坐标以人类参考基因组 hg38 为基准。